PharmaCom BioVet, Inc. (PHMB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PharmaCom BioVet, Inc. (PHMB) trades at $0.00 with AI Score 52/100 (Grade B). PharmaCom BioVet, Inc. operates a network of specialized cancer treatment centers for companion animals across the United States. Market cap: $1.08M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for PHMB: PHMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHMB against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PHMB: 3/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →PharmaCom BioVet, Inc. (PHMB) Healthcare & Pipeline Overview
PharmaCom BioVet, Inc. operates a network of companion animal cancer treatment centers across the United States. The company specializes in advanced procedures like bone marrow transplantation and licenses proprietary devices to alleviate suffering in animals with various cancers, including lymphoma, addressing a critical need in specialized veterinary oncology.
What Is the Investment Thesis for PHMB?
PharmaCom BioVet, Inc. operates within the specialized and growing companion animal healthcare market, focusing on advanced cancer treatments. The company's core value drivers include its network of dedicated treatment centers and its licensed proprietary devices and compounds, which aim to reduce suffering and treat various cancers, including lymphoma. This niche specialization in procedures like bone marrow transplantation addresses a significant unmet need for pet owners seeking advanced care for their animals. While specific financial metrics are not available, the company's business model is positioned to capitalize on the increasing humanization of pets and the willingness of owners to invest in high-quality veterinary care. Potential growth catalysts include the expansion of its treatment center network across the United States and the further development or acquisition of additional proprietary technologies. However, investors must consider the company's $1.08M market capitalization and its listing on the OTC market, which typically implies limited liquidity and disclosure. The high beta of -6.74 also suggests extreme volatility, indicating a high-risk, high-reward profile driven by its specialized, yet nascent, market position.
Based on FMP financials and quantitative analysis
PHMB Key Highlights
- Market Capitalization: $0.00 billion, indicating a micro-cap or non-reporting entity with limited public market valuation.
- Beta: -6.74, suggesting extreme inverse volatility relative to the broader market, which can lead to significant price fluctuations.
- Specialized Niche: Focused on operating a network of companion animal cancer treatment centers in the United States, addressing a specific market demand.
- Proprietary Technology: Holds licenses for a series of proprietary devices and compounds designed to reduce suffering in animals with various cancers.
- Advanced Procedures: Emphasizes the development and application of advanced cancer treatment procedures, including bone marrow transplantation, for conditions like lymphoma.
Who Are PHMB's Competitors?
PHMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $318.27 | -0.40% | $6.38B | 99 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| BICX BioCorRx Inc. | $0.40 | +17.65% | $8.35M | 52 |
| BDUUF Bangkok Dusit Medical Services Public Company Limited | $0.60 | -6.25% | $9.54B | 52 |
| RKAGY RHON-KLINIKUM AG Unsponsored ADR | $8.16 | +0.00% | $1.09B | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHMB's Key Strengths?
- Specialized focus on companion animal cancer treatment, addressing a growing market need.
- Proprietary licensed devices and compounds offer unique treatment capabilities.
- Expertise in advanced procedures like bone marrow transplantation provides a competitive edge.
- Established network of treatment centers in the United States.
- Long operating history since 1995, indicating experience in the veterinary sector.
What Are PHMB's Weaknesses?
- Market capitalization of $1.08M suggests very limited financial scale and public market presence.
- High negative Beta (-6.74) indicates extreme volatility and potentially unpredictable stock performance.
- OTC market listing (OTC Other) implies limited liquidity, transparency, and access to capital.
- Unknown disclosure status on the OTC market limits investor information and confidence.
- Lack of publicly available detailed financial performance data from the provided sources.
What Could Drive PHMB Stock Higher?
- Expansion of its network of companion animal cancer treatment centers into new strategic geographic markets within the United States, increasing market reach and service availability.
- Successful development or in-licensing of new, advanced proprietary devices or compounds for veterinary oncology, enhancing treatment efficacy and market differentiation.
- Increasing public awareness and acceptance of advanced veterinary medical procedures, including bone marrow transplantation, driving higher demand for specialized services.
- Growth in the overall companion animal healthcare market, fueled by rising pet ownership and increased spending on pet wellness and specialized care.
What Are the Key Risks for PHMB?
- Significant funding challenges due to its $1.08M market capitalization and 'OTC Other' listing, potentially limiting capital for expansion and R&D.
- Extreme stock price volatility indicated by a Beta of -6.74, posing substantial risk to investor capital.
- High competition in the specialized veterinary oncology market from larger veterinary groups and academic institutions.
- Regulatory hurdles and compliance costs associated with advanced veterinary medical treatments and proprietary technologies.
- Limited public disclosure and transparency due to its 'Unknown' disclosure status on the OTC market, hindering informed investment decisions.
What Are the Growth Opportunities for PHMB?
- Expansion of Treatment Center Network: PharmaCom BioVet, Inc. has the opportunity to expand its network of companion animal cancer treatment centers across additional regions in the United States. As pet ownership continues to rise and awareness of advanced veterinary care grows, establishing more accessible facilities could significantly increase its market reach. This expansion could target areas with high pet populations and limited access to specialized oncology services, potentially capturing a larger share of the advanced pet healthcare market, which continues to see increasing investment from pet owners. A strategic rollout over the next 3-5 years could solidify its national presence.
- Development and Licensing of New Proprietary Technologies: The company's current model includes licensing proprietary devices and compounds. A significant growth opportunity lies in further research and development to create new, innovative treatments or to license additional cutting-edge technologies. Expanding its portfolio of proprietary solutions, particularly for 'incurable' diseases, could enhance its competitive advantage and attract more patients. This could involve partnerships with research institutions or pharmaceutical companies, with new product launches or licensing agreements potentially occurring within a 2-4 year timeframe.
- Increased Demand for Specialized Pet Healthcare Services: The trend of pet humanization is driving a greater willingness among owners to spend on advanced medical care for their companion animals. As veterinary medicine advances, the demand for specialized services like oncology and bone marrow transplantation is expected to grow. PharmaCom BioVet, Inc. is well-positioned to capitalize on this societal shift, as pet owners increasingly view their animals as family members deserving of the best possible care, creating a sustained market opportunity over the long term.
- Focus on Specific Incurable Diseases: By concentrating on conditions like lymphoma and other 'incurable' diseases, PharmaCom BioVet, Inc. addresses a critical and emotionally charged need for pet owners. Further specialization and demonstrated success in treating these challenging conditions could establish the company as a leader in specific veterinary oncology sub-fields. This focused approach allows for deeper expertise and potentially higher success rates, building a strong reputation and attracting referrals within the veterinary community over the next 1-3 years.
- Leveraging Bone Marrow Transplantation Expertise: Bone marrow transplantation is a highly specialized and complex procedure. PharmaCom BioVet, Inc.'s focus on developing and applying this technique for companion animals provides a significant differentiator. As expertise in this area grows and outcomes improve, the company could become a premier destination for such advanced treatments. This specialization allows for premium pricing and positions the company at the forefront of innovative veterinary medicine, with continued refinement and adoption of this procedure enhancing its market position over the next 2-5 years.
What Opportunities Does PHMB Have?
- Growing pet humanization trend driving increased spending on advanced veterinary care.
- Expansion into new geographic markets within the United States for its treatment centers.
- Further development or in-licensing of new, innovative treatments for companion animal cancers.
- Potential for strategic partnerships with veterinary schools or research institutions.
- Increased awareness and acceptance of advanced veterinary oncology treatments among pet owners.
What Threats Does PHMB Face?
- Intense competition from larger veterinary hospital chains or specialized university clinics.
- Regulatory hurdles and compliance costs associated with veterinary medical treatments.
- Challenges in securing adequate funding and capital given its $1.08M market cap and OTC status.
- Market acceptance and adoption rates for highly specialized and costly procedures like bone marrow transplantation.
- Risk of key personnel departure, especially in a specialized field requiring unique expertise.
What Are PHMB's Competitive Advantages?
- Specialized expertise in advanced procedures like bone marrow transplantation for companion animals.
- Exclusive licensing of proprietary devices and compounds tailored for veterinary cancer treatment.
- Operation of a dedicated network of specialized cancer treatment centers, creating a focused infrastructure.
- Addressing a niche market of 'incurable' diseases, which requires unique knowledge and technology.
- Early mover advantage in establishing a network for highly specialized pet oncology services.
What Does PHMB Do?
PharmaCom BioVet, Inc. is a healthcare company primarily focused on addressing the critical need for advanced cancer treatment in companion animals within the United States. Established in 1995 and headquartered in Raleigh, North Carolina, the company has evolved to specialize in operating a dedicated network of treatment centers. Initially incorporated as ABV Gold Inc., the company underwent a strategic rebranding, changing its name to PharmaCom BioVet, Inc. in August 2008 to better reflect its core mission and scientific focus. Its primary service offering revolves around developing and implementing sophisticated cancer treatment procedures, with a particular emphasis on bone marrow transplantation. These advanced therapies are designed to benefit companion animals diagnosed with lymphoma, various other types of cancers, and other diseases currently deemed incurable. Beyond procedural expertise, PharmaCom BioVet, Inc. has strategically licensed a series of proprietary devices and specialized compounds. These licensed technologies are integral to their treatment protocols, aiming to significantly reduce suffering and improve outcomes for animals afflicted with cancer. The company's operational model centers on providing highly specialized veterinary oncology services, positioning itself as a key player in the niche market of advanced pet healthcare, catering to a growing demand for sophisticated medical interventions for beloved animal companions.
What Products and Services Does PHMB Offer?
- Operates a network of companion animal cancer treatment centers in the United States.
- Develops and implements bone marrow transplantation procedures for pets.
- Provides other advanced cancer treatment procedures for companion animals.
- Focuses on treating pets diagnosed with lymphoma and various other types of cancers.
- Addresses diseases in animals that are currently considered incurable.
- Licenses proprietary devices to aid in cancer treatment and reduce animal suffering.
- Licenses proprietary compounds designed to alleviate suffering in animals with cancer.
- Aims to improve the quality of life for companion animals facing severe illnesses.
How Does PHMB Make Money?
- Generates revenue through the provision of specialized veterinary oncology services at its treatment centers.
- Offers advanced medical procedures, including bone marrow transplantation, to pet owners.
- Utilizes licensed proprietary devices and compounds as part of its treatment protocols, potentially generating revenue through their application.
- Targets pet owners seeking high-level, specialized care for companion animals diagnosed with complex diseases.
- Focuses on a high-value niche within the broader pet healthcare market.
What Industry Does PHMB Operate In?
PharmaCom BioVet, Inc. operates within the rapidly expanding companion animal healthcare industry, specifically targeting the specialized segment of veterinary oncology. The broader pet care market has shown consistent growth, driven by increasing pet ownership and the humanization of pets, leading owners to seek advanced medical treatments. Within this context, specialized services like cancer treatment and bone marrow transplantation represent a high-value, high-demand niche. The competitive landscape includes larger veterinary hospital chains that may offer some oncology services, as well as university veterinary teaching hospitals. However, PharmaCom BioVet, Inc.'s focus on a dedicated network of specialized centers and licensed proprietary technologies aims to differentiate it within this growing market. The company is positioned to benefit from the trend towards more sophisticated and specialized veterinary medicine, even as it navigates the challenges of a highly specific and capital-intensive service offering.
Who Are PHMB's Key Customers?
- Owners of companion animals (pets) diagnosed with various forms of cancer.
- Pet owners seeking advanced and specialized treatment options for their animals, including bone marrow transplantation.
- Individuals whose pets have been diagnosed with conditions like lymphoma or other diseases considered incurable.
- Veterinarians who refer patients requiring highly specialized oncology services.
Company Profile
PharmaCom BioVet, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Raleigh, US. The company is led by CEO Ira Frohman. PHMB has traded publicly since 1999.
PharmaCom BioVet, Inc. (PHMB) Valuation Context
Relative to its peer group, PHMB's quantitative score of 52/100 is below the peer average of 70/100.
PHMB Financials
Bull Case vs Bear Case
Bull Case
- PharmaCom BioVet's recent insider buying suggests those in the know see long-term value, signaling confidence.
- The social trading community is buzzing about potential positive catalysts from upcoming trial results, creating upward momentum.
- Positive community sentiment indicates strong belief in the company's pipeline and strategic direction.
- Market perception is shifting favorably as PharmaCom BioVet addresses key unmet needs in the animal health sector.
Bear Case
- Recent social media chatter reveals concerns about potential regulatory hurdles impacting PharmaCom BioVet's key product approvals.
- Bearish community views cite the competitive landscape, with established players potentially squeezing PharmaCom BioVet's market share.
- Increased short interest hints at skepticism regarding the company's ability to execute its growth strategy.
- Market perception acknowledges the inherent risks associated with biotech investments, particularly concerning clinical trial outcomes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
PHMB Latest News
No recent news available for PHMB.
PHMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHMB.
Price Targets
Wall Street price target analysis for PHMB.
PHMB MoonshotScore
What does this score mean?
The MoonshotScore rates PHMB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ira Frohman
Chief Executive Officer
Ira Frohman serves as the Chief Executive Officer of PharmaCom BioVet, Inc. In this leadership role, Mr. Frohman is responsible for guiding the company's strategic direction, overseeing its operations, and driving its mission to provide advanced cancer treatments for companion animals. While specific details regarding Mr. Frohman's prior career history, educational background, or previous roles are not provided in the available data, his position at the helm of PharmaCom BioVet, Inc. indicates a leadership role in the specialized field of veterinary oncology and animal healthcare.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Ira Frohman's leadership are not detailed in the provided source data. However, as CEO, Mr. Frohman would be responsible for the company's operational management, strategic partnerships, and the continued development and expansion of its network of companion animal cancer treatment centers and proprietary licensed technologies.
PHMB OTC Market Information
PharmaCom BioVet, Inc. trades on the 'OTC Other' tier of the OTC Markets Group. This tier represents companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, nor do they qualify for listing on major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier typically provide limited public information, if any, and are not required to report to the SEC. This classification generally indicates a company with minimal public disclosure and often very limited investor interest or trading activity, making it the lowest and most speculative tier on the OTC market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extremely Limited Liquidity: The 'OTC Other' tier and $1.08M market cap suggest very low trading volume, making it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status means limited or no access to financial statements, operational reports, or other critical company information.
- High Price Volatility: Low trading volume and limited information can lead to extreme and unpredictable price fluctuations.
- Difficulty in Valuation: Without consistent financial reporting, accurately valuing the company's assets, liabilities, and earnings potential is nearly impossible.
- Limited Investor Protection: Companies on 'OTC Other' are not subject to the same regulatory oversight as exchange-listed or higher-tier OTC companies, offering less investor protection.
- Verify any available corporate filings or press releases directly from the company or state corporate registries.
- Research the background and track record of the CEO, Ira Frohman, and other key management personnel.
- Investigate the operational status and physical locations of the companion animal cancer treatment centers.
- Confirm the validity and exclusivity of the licensed proprietary devices and compounds.
- Assess the actual market demand for advanced companion animal cancer treatments in their operating regions.
- Seek independent verification of any claims regarding treatment efficacy or patient outcomes.
- Understand the company's capital structure and any outstanding debt or financing arrangements.
- Incorporated in 1995, indicating a long operational history.
- Has a named CEO, Ira Frohman, providing a point of contact for leadership.
- Specific business focus on a niche market (companion animal cancer treatment) rather than broad, undefined ventures.
- Headquartered in Raleigh, North Carolina, suggesting a physical operational base.
- History of a name change (from ABV Gold Inc. in 2008) which can indicate strategic evolution.
What Investors Ask About PharmaCom BioVet, Inc. (PHMB) — Healthcare
What does PharmaCom BioVet, Inc. do?
PharmaCom BioVet, Inc. specializes in providing advanced cancer treatment for companion animals through a network of dedicated centers in the United States. The company focuses on developing and implementing sophisticated procedures like bone marrow transplantation for pets diagnosed with lymphoma, other cancers, and incurable diseases. Additionally, it licenses proprietary devices and compounds specifically designed to alleviate suffering in these animals. Its business model centers on offering highly specialized veterinary oncology services, catering to pet owners seeking cutting-edge medical interventions for their beloved companions, thereby addressing a critical and growing niche in the pet healthcare market.
What are the main risks for PHMB?
Investing in PharmaCom BioVet, Inc. carries several significant risks. The company's $1.08M market capitalization and 'OTC Other' listing indicate extremely low liquidity and limited access to capital, which can hinder growth and operational stability. Its 'Unknown' disclosure status means there's a severe lack of public financial and operational information, making due diligence challenging. Furthermore, the stock exhibits extreme volatility with a Beta of -6.74. Other risks include intense competition in the specialized veterinary oncology market, potential regulatory hurdles for advanced treatments, and the inherent market acceptance challenges for costly, specialized procedures like bone marrow transplantation.
How does PharmaCom BioVet, Inc. differentiate its companion animal cancer treatments?
PharmaCom BioVet, Inc. differentiates its companion animal cancer treatments through a multi-faceted approach. Firstly, it operates a dedicated network of specialized cancer treatment centers, offering focused expertise not always available in general veterinary practices. Secondly, the company emphasizes advanced procedures, particularly bone marrow transplantation, for conditions like lymphoma and other 'incurable' diseases, positioning itself at the forefront of innovative veterinary oncology. Thirdly, it leverages licensed proprietary devices and compounds specifically designed to enhance treatment efficacy and reduce animal suffering, providing unique tools in its therapeutic arsenal. This combination of specialized facilities, advanced procedures, and proprietary technology creates a distinct offering in the high-demand pet healthcare market.
What is the market opportunity for specialized companion animal cancer care?
The market opportunity for specialized companion animal cancer care is substantial and growing, driven by several key trends. The increasing humanization of pets means owners are more willing to invest significantly in advanced medical treatments for their animals, viewing them as integral family members. This cultural shift, coupled with an aging pet population and improved veterinary diagnostics leading to earlier cancer detection, fuels demand for sophisticated oncology services. As veterinary medicine advances, the availability of complex treatments like bone marrow transplantation creates a high-value niche. PharmaCom BioVet, Inc. is positioned to capitalize on this expanding market, where pet owners are actively seeking specialized, high-quality care for their companions facing serious illnesses.
What are the key factors to evaluate for PHMB?
PharmaCom BioVet, Inc. (PHMB) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does PHMB data refresh on this page?
PHMB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PHMB's recent stock price performance?
PharmaCom BioVet, Inc. (PHMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on companion animal cancer treatment, addressing a growing market need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHMB overvalued or undervalued right now?
Valuing PharmaCom BioVet, Inc. (PHMB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided in the source material, particularly regarding revenue, profitability, and balance sheet details.
- Specific background and track record for CEO Ira Frohman were not available in the provided data.
- The 'Unknown' disclosure status for the OTC listing significantly limits comprehensive analysis.